Abstract:While immunotherapy has revolutionized the treatment of several cancer types, some patients do not respond to current therapies. The CD40-CD40L pathway is crucial for activating antigen-presenting cells and initiating antitumor T-cell responses. CD40 is a TNF receptor superfamily member expressed on antigen-presenting cells (APCs, e.g. monocytes and dendritic cells). Several CD40 agonistic antibodies (Abs) have been tested in past clinical trials, however, their efficacy has been limited and accompanied by dose-limiting toxicities (DLT). Thus, CD40 agonism necessitates optimization to allow efficient mobilization of the immune system to fight cancer, while minimizing toxicity. We hypothesize that engagement of CD40 expressed by APCs, will lead to maturation and activation of APCs, enhance antigen presentation and promote recruitment of cytotoxic CD8 T-cells, resulting in tumor elimination. We have previously demonstrated that when the Fc portion of anti-CD40 Abs binds to the inhibitory Fc-Receptor (FcR) FcRIIB, which is expressed on various leukocytes - it provides the necessary crosslinking for CD40 trimerization, promotes CD40 signaling and leads to activation of CD40-expressing APCs. Thus, we engineered the Fc of a human IgG1 anti-CD40 agonistic Ab (clone 2141) by introducing several point mutations (termed herein: the V11 modification) to selectively increase its binding affinity to FcRIIB. To mitigate systemic adverse events - we switched from systemic to in situ administration (injecting the Abs directly into lesions). Finally, we generated an immunocompetent mouse strain that expresses human CD40 and human FcRs, while lacking murine CD40 and murine FcRs (termed herein: hCD40/hFcR mice). We implanted orthotopic murine tumor cells into hCD40/hFcR mice, and treated in situ with the optimized CD40-targeting Ab, 2141-V11. Our findings demonstrate that the Ab leads to the complete elimination of primary tumors. In a bilateral tumor challenge, both tumors fully regress, despite treating only a single tumor. This abscopal effect suggests a robust systemic immune activation, which was supported by an increase in serum cytokine levels such as IFNg, TNFa, IL-15, IL-18, CXCL10, CCL7 and IL-6. Multiplex IHC staining of regressing tumor sections demonstrated formation of tertiary lymphoid structures (TLS). Finally, mice that have rejected the tumors were protected from tumor re-challenge, suggesting durable antitumor immune memory. Following the in vivo findings and pre-clinical toxicology studies in Non-Human Primates, we conducted a Phase I, 3+3 dose escalation trial (n=12), in which 2141-V11 was injected into one/two lesions (NCT04059588). Complete responses (CR) were observed in two patients and stable disease (SD) in six patients, with no DLTs. Moreover, biopsy and serum analyses from treated patients confirmed our in vivo findings (TLS formation and increase in cytokine serum levels). Overall, we show the efficacy and safety of intra-tumoral Fc-optimized CD40 Ab therapy and unveil a potential unique mechanism of action of this immunotherapy. Citation Format: Polina Weitzenfeld, Juan C Osorio, Jeffrey V Ravetch. Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity - From the bench to the bedside and back [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-11.

Abstract 4169: A bifunctional anti-PDL-1 antibody/IL-10 fusion protein targeting exhausted T cells for cancer immunotherapy

Abstract 2717: Bifunctional fusion protein PDL1sFv/MICAe for cancer immunotherapy

Abstract 4057: Beyond IL-2: The promise of anti PD-1-attenuated IL-2 fusion protein in cancer immunotherapy

Abstract 2361: A PD1-antibody-attenuated IL-2 fusion protein activates immune cells leading to the inhibition of tumor growth in ex vivo human 3D tumor models

Abstract 5515: Combination of recombinant murine IL-12 and anti-PD-1 induced synergistic anti-tumor response

845 A colony stimulating factor 1 receptor-blocking bifunctional protein simultaneously targets tumor-associated macrophages and exhausted T cells for the treatment of triple-negative breast cancer

Abstract 719: A tumor-activated PD1/IL2 bispecific molecule, designed to overcome IL-2 receptor-mediated clearance, improve tolerability and stimulate antigen-experienced CD8+ T cells in the tumor microenvironment of murine models

Abstract 4080: IBB0979, A novel B7H3/IL-10 immunocytokine of monovalent anti-B7H3 antibody fused with IL-10 homodimer

Abstract 5657: HK010, a novel anti-PDL1 × CD137 bispecific antibody, exhibits potent anti-tumor immunity and low toxicity

Abstract 2365: Disrupting IL-11/IL-11R signaling by an efficacious anti-IL-11 antibody 9MW3811 enhances T cell tumor infiltration and synergizes with anti-PD-1 therapies in vivo

Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

Abstract 2726: A novel trispecific antibody HC010 targeting PD-1/CTLA-4/VEGF for the potential treatment in anti-PD-1 antibody resistant NSCLC patients

Abstract 2475: MB5029: A novel anti-PD-1 x IL-2v with improved safety profile and enhanced anti-tumor efficacy by selectively targeting activated T cells

Abstract 4083: Pre-clinical development of IAMA-005, a long-acting cytokine fusion of modified IL-2 and IFN-α

Abstract 2728: Discovery of a multispecific CD73/PD-1 targeting drug Fc-conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Abstract 4106: A novel synthetic long peptide vaccine composition targeting multiple PD-L1 T-cell epitopes exhibits anti-tumor efficacy in a syngeneic mouse colorectal cancer model

Abstract 2963: CDX-585, a novel bispecific antibody targeting PD-1 and ILT4

Abstract 5671: MB201, a CD8+ T cell-selective anti-PD-L1 x IL-2 variant fusion protein, exhibits a potent anti-tumor efficacy without peripheral toxicity

Abstract 4075: Targeting attenuated IL-18 to PD-1: A next generation checkpoint inhibitor with enhanced anti-tumor activity

Abstract PR-11: Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity - From the bench to the bedside and back

An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses